These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. DNA vaccines for malaria: the past, the present, & the future. Doolan DL; Hedstrom RC; Wang R; Sedegah M; Scheller LF; Hobart P; Norman JA; Hoffman SL Indian J Med Res; 1997 Aug; 106():109-19. PubMed ID: 9291681 [TBL] [Abstract][Full Text] [Related]
7. Towards a vaccine against malaria. McGregor IA Br J Biomed Sci; 1993 Mar; 50(1):35-42. PubMed ID: 8032294 [TBL] [Abstract][Full Text] [Related]
9. The development of malaria vaccines: SPf66--what next? Tanner M; Alonso PL Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632 [TBL] [Abstract][Full Text] [Related]
10. [Malaria vaccines--which vaccines to whom?]. Jepsen S Tidsskr Nor Laegeforen; 2000 May; 120(14):1665-8. PubMed ID: 10901079 [TBL] [Abstract][Full Text] [Related]
11. Development of vaccines for Plasmodium vivax malaria. Mueller I; Shakri AR; Chitnis CE Vaccine; 2015 Dec; 33(52):7489-95. PubMed ID: 26428453 [TBL] [Abstract][Full Text] [Related]
12. Adjuvants for malaria vaccines. Coler RN; Carter D; Friede M; Reed SG Parasite Immunol; 2009 Sep; 31(9):520-8. PubMed ID: 19691556 [TBL] [Abstract][Full Text] [Related]
13. [Current state and problems of the development of malaria vaccine]. Tanabe K Nihon Rinsho; 1996 Aug; 54(8):2252-60. PubMed ID: 8810805 [TBL] [Abstract][Full Text] [Related]
14. New concepts in vaccine development in malaria. Kanoi BN; Egwang TG Curr Opin Infect Dis; 2007 Jun; 20(3):311-6. PubMed ID: 17471043 [TBL] [Abstract][Full Text] [Related]
15. New malaria vaccines roadmap targets next generation products by 2030. Partners agree approach for developing vaccines capable of reducing malaria cases by 75%, and to enable malaria elimination. Cent Eur J Public Health; 2013 Dec; 21(4):206. PubMed ID: 24592725 [No Abstract] [Full Text] [Related]
16. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
18. A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus. Tamminga C; Kavanaugh M; Fedders C; Maiolatesi S; Abraham N; Bonhoeffer J; Heininger U; Vasquez CS; Moorthy VS; Epstein JE; Richie TL Vaccine; 2013 Aug; 31(35):3628-35. PubMed ID: 23395586 [TBL] [Abstract][Full Text] [Related]
19. Combined efforts in immunology and vaccinology will lead to effective vaccines against HIV, tuberculosis and malaria. Chiodi F; Kaufmann SH J Intern Med; 2014 May; 275(5):442-3. PubMed ID: 24635534 [No Abstract] [Full Text] [Related]
20. The future for blood-stage vaccines against malaria. Richards JS; Beeson JG Immunol Cell Biol; 2009 Jul; 87(5):377-90. PubMed ID: 19417768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]